Lena Q51

In January 2023, the company will launch LENA Q51 the first Leukemia diagnostic tests able to test up to 51 genes mutations.

The medical community has historically defined, and treated cancer based on where it is found in the body, such as the breast, lung, or Leukemia.

The FDA has recently started to approve treatments based on the genetic makeup of cancer rather than where the cancer is located.

Sequencing a patient’s DNA continues to become faster and cheaper. More patients now have a window into their genetic codes to better understand how changes in their genes can lead to diseases like cancer.

Sequencing helps us to understand if a genetic mutation in, say, breast cancer is like a genetic mutation linked to colon cancer. If that is the case, a patient with this type of breast cancer may benefit from a treatment used for colon cancer, rather than one used to treat breast cancer. A very innovative path to successfully treat cancer and life-threatening illnesses.

The innovative approach of LENA Q51 the Leukemia Fusion Gene Kit is to target the gene mutations, the clonogenic gene rearrangements and abnormal gene expression. Fusion genes are one of the most common biomarkers in Leukemia and are caused by chromosome breakage and recombination.

More than 200 types of fusion genes have been identified, and about 50% of leukemia patients have fusion gene biomarkers, and different disease subtypes have different fusion gene profiles. The genetic approach of LENA Q51 allows the screening of up to 51 types of leukemia fusion genes

Leukemia is a deadly blood disease that affects about 200 genes in the human genome. So far, the most advanced test that is still in R&D but has been announced is a test that could detect up to 14 genes mutation. Until 2022 the only Leukemia test done were testing 2 genes mutation.

LENA Q51 is detecting 51 genes mutation thus a very significant technological and medical advance.

The process is spectacular as the test can be administered in a qPCR machine and deliver the results within less than 3 hours. Compared to the current detection system for Leukemia the process is light speed ahead. In the traditional system to detect Leukemia, you need to undertake blood tests followed by bone marrow biopsy. It is time consuming, and it is also significantly very expensive and subject to interpretation as cytology remains to the human interpretation. This process takes an average of 3 to 6 weeks.Lena Q51 takes less than 3 hours. Costs of the LENA Q51 is a fraction of the traditional bone marrow biopsy

LENA Q51 is detecting 51 genes mutation thus a very significant technological and medical advance.

The process is spectacular as the test can be administered in a qPCR machine and deliver the results within less than 3 hours. Compared to the current detection system for Leukemia the process is light speed ahead. In the traditional system to detect Leukemia, you need to undertake blood tests followed by bone marrow biopsy. It is time consuming, and it is a subjective interpretation as cytology remains to the human interpretation. This process takes an average of 3 to 6 weeks. Lena Q51 takes less than 3 hours. Costs of the LENA Q51 is a fraction of the traditional bone marrow biopsy.

FDA Disclaimer: Lena Q 51 is offered only to professionals as “Research Use Only (RUO) not for diagnostics purpose.

Lena Q51 received a CE conformity certificate